Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Net Income (2019 - 2025)

Historic Net Income for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to -$7.3 million.

  • Keros Therapeutics' Net Income rose 8625.27% to -$7.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.4 million, marking a year-over-year increase of 13432.12%. This contributed to the annual value of -$187.4 million for FY2024, which is 2245.93% down from last year.
  • Per Keros Therapeutics' latest filing, its Net Income stood at -$7.3 million for Q3 2025, which was up 8625.27% from -$30.7 million recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' Net Income ranged from a high of $148.5 million in Q1 2025 and a low of -$53.0 million during Q3 2024
  • Over the past 5 years, Keros Therapeutics' median Net Income value was -$29.7 million (recorded in 2022), while the average stood at -$21.6 million.
  • As far as peak fluctuations go, Keros Therapeutics' Net Income tumbled by 32821.33% in 2022, and later skyrocketed by 44432.2% in 2025.
  • Keros Therapeutics' Net Income (Quarter) stood at -$6.9 million in 2021, then plummeted by 328.21% to -$29.7 million in 2022, then tumbled by 56.32% to -$46.5 million in 2023, then grew by 0.92% to -$46.0 million in 2024, then soared by 84.18% to -$7.3 million in 2025.
  • Its Net Income stands at -$7.3 million for Q3 2025, versus -$30.7 million for Q2 2025 and $148.5 million for Q1 2025.